Literature DB >> 24530215

β-Blockers and atrial fibrillation: hypertension and other medical conditions influencing their use.

Paul Dorian1, Paul Angaran2.   

Abstract

β-Blockers are among the most frequently used drugs in patients with atrial fibrillation. They are often used for ventricular rate control, acutely in emergency situations and chronically, in patients with persistent or permanent atrial fibrillation. They are also used, with less evidence of benefit, to prevent the first occurrence or recurrence of atrial fibrillation, particularly in patients with hypertension. They are effective in reducing ventricular rate, potentially leading to an improvement in symptoms and well-being. They are particularly indicated in patients with heart failure and atrial fibrillation; the choice of β-blockers in this condition should be guided by tolerability and effects on symptoms and well-being.
Copyright © 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24530215     DOI: 10.1016/j.cjca.2013.09.029

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  3 in total

1.  Oral carvedilol in escalating doses in the acute treatment of atrial fibrillation.

Authors:  Ravi Venkatachelam Chitrapu; Pentakota Ramana Rao; Gangireddy Venkateswara Reddy
Journal:  J Pharmacol Pharmacother       Date:  2014-10

Review 2.  Arrhythmogenic Substrates for Atrial Fibrillation in Obesity.

Authors:  Ellen R Lubbers; Morgan V Price; Peter J Mohler
Journal:  Front Physiol       Date:  2018-10-22       Impact factor: 4.566

3.  Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Arjun K Pandey; Iva Okaj; Hargun Kaur; Emilie P Belley-Cote; Jia Wang; Alireza Oraii; Alexander P Benz; Linda S B Johnson; Jack Young; Jorge A Wong; Subodh Verma; David Conen; Hertzel Gerstein; Jeff S Healey; William F McIntyre
Journal:  J Am Heart Assoc       Date:  2021-08-28       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.